Predictive Oncology's Financial Results Overview
PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a leader in AI-driven drug discovery, has shared remarkable financial and operational results for the third quarter of 2025, along with updates on its digital asset strategy focusing on ATH, the native token of the Aethir network.
Third Quarter Highlights
Recent developments highlight Predictive Oncology's commitment to innovating within the biotechnology and AI landscapes. The company has initiated an active digital asset strategy centered around ATH. This initiative includes private placements resulting in approximately $50.8 million in cash proceeds and in-kind contributions with a notional worth nearing $292.7 million.
Current Digital Asset Strategy
As of early November 2025, Predictive Oncology holds around 5.70 billion ATH, valued at approximately $152.8 million on the Coinbase exchange. Of this, 3.7 billion are locked under various restrictions while 2.0 billion remain unlocked, demonstrating the company's capacity to leverage these assets.
Implications of the Digital Strategy
This strategy enables Predictive Oncology not only to participate actively in the Aethir ecosystem but also to create new revenue streams from its digital holdings. By transforming its AI infrastructure, the firm aims to meet the heightened demand for advanced computing power across various industries.
Financial Performance Summary
Predictive Oncology reported a notable cash position of $181,667 as of the end of the third quarter, a decline from $611,822 at year-end 2024. The firm's stockholders' deficit also significantly decreased to $77.4 million, illustrating a substantial improvement compared to the previous year's figures.
Detailed Financial Metrics
The loss per common share from continuing operations was $(107.24) for the most recent quarter, compared to $(4.99) for the same period in the previous year. This loss primarily stemmed from a derivative liability related to the ATH token strategy.
During the same quarter, total revenue recorded was $3,618, marginally down from $3,907 in the prior year, indicating a stable business performance despite market fluctuations.
Operational and Strategic Developments
Predictive Oncology's operational costs increased to $3.27 million largely due to higher legal fees and stock-based compensation, offset by lower employee expenses driven by a reduced headcount. Research and development expenses remained consistent, signifying a focus on sustaining operational integrity.
Strategic Collaborations
The company has also announced partnerships, including a significant collaboration with Every Cure to advance drug repurposing efforts aimed at improving patient outcomes. These endeavors reinforce Predictive’s commitment to leveraging its AI capabilities for impactful innovations in healthcare.
Future Directions
Looking ahead, Predictive Oncology is optimistic about the potential of its digital asset strategy to empower more robust operational frameworks that democratize AI infrastructure access. The insights from its innovative business lines are expected to play a critical role in transforming how AI is applied in drug discovery.
Raymond Vennare, Chairman and CEO, expressed excitement about the prospects of integrating advanced computing solutions and enhancing AI deployment capabilities across sectors. With the growing market need for reliable AI infrastructure, Predictive Oncology stands at the forefront of a digital transformation, capitalizing on strategic opportunities presented by the Aethir ecosystem.
Frequently Asked Questions
What is Predictive Oncology's primary business focus?
Predictive Oncology specializes in leveraging AI for drug discovery and development, targeted towards enhancing treatment outcomes for cancer patients.
What digital asset strategy has Predictive Oncology initiated?
The company has initiated a treasury strategy focusing on ATH, the native token of the Aethir network, allowing it to enhance its operational capabilities and revenue potential.
How much ATH does Predictive Oncology currently hold?
As of November 10, 2025, Predictive Oncology holds approximately 5.70 billion ATH valued at around $152.8 million.
What were the financial results for Q3 2025?
In Q3 2025, Predictive Oncology reported a revenue of $3,618, a loss per share of $(107.24), and a cash position of $181,667.
Who has been appointed to the board recently?
Shawn Matthews has joined the Board of Directors as a significant addition to the team, bringing extensive experience from his role as CEO at DNA Holdings.
